Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginal Candidiasis
NCT ID: NCT02345096
Last Updated: 2016-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
22 participants
INTERVENTIONAL
2015-01-31
2016-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Saccharomyces cerevisiae CNCM I-3856
In this arm, subjects will be asked to consume one capsule of Saccharomyces cerevisiae CNCM I-3856 per day.
Saccharomyces cerevisiae
placebo
In this arm, subjects will be asked to consume one capsule of placebo per day.
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Saccharomyces cerevisiae
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Regularly menstruating women with normal gynaecological status
* Patient must use a contraception method
* Having given a written informed consent prior to selection
* Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research.
Exclusion Criteria
* Tumors in the genital tract or beast.
* Hypersensitivity to the study product.
* Uterine or vaginal bleeding of unknown origin.
* Use of systemic or intravaginal antibiotic or antifungal agents in the previous 14 days.
* Concomitant medication with antimycotics for other diagnoses.
* Woman with known transmitted infections such as Neisseria gonorrhoea, Chlamydia trachomatis, Treponema pallidum, herpes simplex, Trichomonas vaginalis, human papilloma virus, HIV 1 or 2.
* Immunocompromised individuals.
* Subjects not willing to stop taking probiotics in the form of dietary supplements or convenient goods
* Subject who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development.
* Subject under administrative or legal supervision.
* Subject who participate to a previous study within 3 months.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eurofins Optimed
INDUSTRY
Lesaffre International
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Cherbut, MD
Role: PRINCIPAL_INVESTIGATOR
Independant gynecologist
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eurofins Optimed
Gières, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OP090414.LES
Identifier Type: -
Identifier Source: org_study_id